ReNerve Limited (ASX: RNV) - Share Price

- Current share price for RNV : $0.080

ReNerve Limited (RNV), an ASX-listed company, is an Australian biotechnology company that has altered peripheral nerve surgery with its ready-to-use solutions for peripheral nerve injuries (PNI).

RNV General Information ⁺

ASX Code	RNV
Website	http://www.renerve.com.au
Industry/Sector	Health Care Supplies
Market Cap ($M)	11
RNV Share Price	$0.080
Day High	$0.000
Day Low	$0.000
Last Close	$0.080
RNV Share Price Movement	- ( No change )

Prices as at 16:40, 14 Jul 2026

⁺Security prices are delayed by at least 20 minutes and are indicative only.

ReNerve Limited (RNV) Upcoming Dividends & Yields

Distribution Type	Dividend	Franking	Ex-dividend date	Payment date	Current Price⁺	Price 7D Avg	Dividend Yield

See all dividends from ReNerve Limited (RNV) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

ReNerve Limited (RNV) price-sensitive announcements

RNV - ReNerve Secures up to A$5 Million Funding Facility

ReNerve Limited has secured a convertible note funding facility with RiverFort Global Oppo

ReNerve Limited (RNV)
9 Jul 2026 | 9:05 AM

RNV - ReNerve Secures Marketing Approval in Indonesia

ReNerve Limited, an Australian biotechnology company, has secured marketing approval for i

ReNerve Limited (RNV)
6 Jul 2026 | 10:11 AM

RNV - ReNerve appoints J4 as second Empliq manufacturing partner

ReNerve Limited has appointed J4 as a second manufacturing partner for its Empliq™ product

ReNerve Limited (RNV)
11 Jun 2026 | 9:47 AM

RNV - ReNerve appoints distribution partner for Malaysian Market

ReNerve Limited, an Australian biotechnology company specializing in peripheral nerve inju

ReNerve Limited (RNV)
5 Jun 2026 | 9:15 AM

ReNerve Limited (RNV) Recent ASX Announcements

Company	Sector	Market Cap ($m)	Headline	Release date/time⁺	Price at release⁺	Current price⁺	Gain/Loss
ReNerve Limited (RNV) ORDINARY FULLY PAID	Health Care	$11	Notification regarding unquoted securities - RNV	13 Jul 2026 2:01PM	$0.080	$0.080	fallen by 0%
ReNerve Limited (RNV) ORDINARY FULLY PAID	Health Care	$11	Proposed issue of securities - RNV	9 Jul 2026 9:14AM	$0.079	$0.080	risen by 1.27%
ReNerve Limited (RNV) ORDINARY FULLY PAID	Health Care	$11	ReNerve Secures up to A$5 Million Funding Facility	9 Jul 2026 9:05AM	$0.079	$0.080	risen by 1.27%
ReNerve Limited (RNV) ORDINARY FULLY PAID	Health Care	$11	ReNerve Secures Marketing Approval in Indonesia	6 Jul 2026 10:11AM	$0.080	$0.080	fallen by 0%
ReNerve Limited (RNV) ORDINARY FULLY PAID	Health Care	$11	Notification of cessation of securities - RNV	16 Jun 2026 9:02AM	$0.084	$0.080	fallen by 4.76%
ReNerve Limited (RNV) ORDINARY FULLY PAID	Health Care	$11	Clarification of Key Terms STC Distribution Agreement	16 Jun 2026 9:01AM	$0.084	$0.080	fallen by 4.76%

RNV Financial Summary

Year to Jun	NPAT	EPS	EPS chg (%)	Yield (%)	Franking (%)
2025A	-$3.73	-$3.00	44.30%	0.00%	0.0%
2024A	-$2.98	-$2.10	65.40%	0.00%	0.0%
2023A	-$1.80	-$1.30	2.40%	0.00%	0.0%

RNV Peer Comparison

Company	Mkt Cap	EPS Growth (%)			P/E (%)			Dividend Yield (%)
Company	Mkt Cap	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A	2023 A	2024 A	2025 A
Ansell Limited (ANN)	$4,388M	0.2270	0.0601	0.1435	16.3435	15.4176	13.4831	2.45%	2.94%	3.35%
Nanosonics Limited (NAN)	$968M	0.5929	0.0000	0.0000	48.4305	0.0000	0.0000	0.00%	0.00%	0.00%
Polynovo Limited (PNV)	$701M	1.5200	0.0000	0.0000	53.7037	0.0000	0.0000	0.00%	0.00%	0.00%
ReNerve Limited (RNV)	$11M	0.4429	0.0000	0.0000	0.0000	0.0000	0.0000	0.00%	0.00%	0.00%

RNV Market Comparison

	Earnings	P/E Ratio	P/B Ratio	P/E Growth
Company	0.00	0.00	2.19	0.00
Market	0.29	13.10	1.14	0.59
Sector	0.69	22.30	1.65	2.02

RNV Directors

Name	Position	Start Date
Dr Julian John Chick	Chief Executive Officer, Executive Director	16 Sep 2016
Ms Maja Aleksandra McGuire	Interim Chairman, Non-Executive Director	4 Dec 2025
Mr Paul Savage	Non-Executive Director	4 Dec 2025

ReNerve Limited (RNV) Changes in Directors' Interest & Trades

Date of change	Director	Buy/Sell	Security Type	Qty	Trade Price	Value
25 Sep 2025	CHICK, Julian	Buy	Indirect Shares	300,000	$0.100	$30,000.000
25 Sep 2025	COOPER, Reginald Stephen	Buy	Indirect Shares	100,000	$0.100	$10,000.000
8 May 2025	COOPER, Reginald Stephen	Buy	Indirect Shares	194,915	$0.114	$22,190.650

See all changes in directors' interest & trades for ReNerve Limited (RNV) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

RNV Management

Name	Position
David Lilja	Chief Financial Officer,Company Secretary

RNV Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in ReNerve Limited (RNV). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding	Name
10,170,788 (7.14%)	Zetland Road Pty Ltd
8,075,618 (5.67%)	Ropehawn Investments Pty Ltd

RNV Calendar of Events

Date	Event
25 February 2027	Report (Interim)
28 August 2026	Report (Annual)
28 August 2026	Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.

What our members say about us